These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 16323216)

  • 1. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MuSK myasthenia gravis with prolonged remission.
    Bouwyn JP; Magnier P; Bédat-Millet AL; Ahtoy P; Maltête D; Lefaucheur R
    Neuromuscul Disord; 2016 Jul; 26(7):453-4. PubMed ID: 27161384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis with antibodies to MuSK: an update.
    Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M
    Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy for anti-MuSK antibody positive myasthenia gravis].
    Pál Z; Boczán J; Bereznai B; Lovas G; Molnár MJ
    Orv Hetil; 2011 Sep; 152(39):1586-9. PubMed ID: 21920845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 6. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
    Yamada C; Teener JW; Davenport RD; Cooling L
    J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in refractory MuSK antibody myasthenia gravis.
    Thakre M; Inshasi J; Marashi M
    J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
    Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
    Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
    Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
    [No Abstract]   [Full Text] [Related]  

  • 17. [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report].
    Nakahama Y; Kawajiri M; Ochi M; Kohara K; Ohta K; Miki T
    Rinsho Shinkeigaku; 2007 Jun; 47(6):356-8. PubMed ID: 17633110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase].
    Hain B; Hanisch F; Deschauer M
    Nervenarzt; 2004 Apr; 75(4):362-7. PubMed ID: 15042294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of myasthenia gravis with anti-MuSK antibodies showing a dramatic improvement with plasma exchange].
    Suzuki H; Motomura M; Yoshimura T; Shiraishi H; Mitsui Y; Hasegawa T; Atsumi M; Kitaguchi M; Kusunoki S
    Rinsho Shinkeigaku; 2005 Jul; 45(7):510-3. PubMed ID: 16119834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.